AlgenBrain AI meets CRISPR for rapid, scaled decoding of cellular networks, uncovering effective intervention points through disease trajectory reverse engineering
Problem
Human diseases are complex & progressive.
The ways we approach drug discovery do not match the reality.
The Status Quo
Other CRISPR-based platforms
Crude phenotypes
Lack of clinically relevant endpoints
Labor intensive target prioritization
Other AI-based platforms
Built on correlation
Image-based phenotyping
No direct biological validation
Solution
We unravel complex biology using precision gene modulation to pinpoint causal signaling pathways that reverse the molecular landscape of disease progression, illuminating routes to novel therapeutics
Drug disovery partners
Our breakthrough is fueled by proprietary CRISPR and AI to redefine the boundaries of disease understanding at unparalleled precision and scale
Built from bottom to top on human biology to accelerate therapeutics to clinic
CRISPR data creation at scale
Proprietary, industrial scale tunable gene modulation system, and world class wet-lab workflow
Proprietary single-cell CRISPR data in which every single causal gene in our genome can be fine-tuned in a wide range of modulation levels
End-to-end in-house wet lab expertise.
1
Innovation spanning the breadth of drug discovery
A preclinical pipeline with a development candidate and lead molecules
Drug discovery partnerships with global pharma companies
Patient relevant disease modeling
3
CRISPR data learning at scale
Proprietary foundation models to map causal disease trajectories and reversal
Models disease progression by capturing billions of dynamic RNA changes in human, disease-relevant cell types and linking them to functional outcomes and therapeutic index through high-throughput gene modulation
2
Values we bring
CRISPR data creation and learning at scale
Robust and repeatable processes and ever-growing CRISPR modulation data universe poised to elucidate impactful disease biology across multiple indications
Translatability from bench to bedside
From first-in-class, human-centric discovery to best-in-class drug development, actionable therapeutic insights derived from our technology offer unprecedented depth to maximize translatability and drug therapeutic index
Precision Medicine
Our high-resolution disease context delineates the full landscape of disease severity and cell states, revealing effective intervention points for stage-specific and cell type-specific precision targets
Enabling end to end technology solutions
We are leveraging AlgenCRISPR and AI to redefine possibilities in biology across drug discovery value chain
Disease Modeling
Quantify and improve clinical relevance of in vitro models to translate discovery from bench to bedside
Target
Novel, high-confidence targets to reverse casual disease progression
Molecule
On-target and safe drug candidates matching desired patient response profile
Clinical Translation
Pipeline
Therapeutic Area
Programs
Discovery
Lead Discovery
Preclinical
Clinical
Precision Oncology
AB-2 Advanced solid Tumors
AB-1 Advanced solid Tumors
Immunology
Inflammation
Undisclosed
Our disease-agnostic platform enables the discovery of transformative medicines across multiple therapeutic frontiers including oncology, immunology, metabolism.
